In conclusion, we show that pharmacological inhibition of DHCR24 increases desmosterol to prevent diet‐induced hepatic steatosis and inflammation, two main hallmarks of NAFLD/NASH development, without inducing hyperlipidemia. Here, DHCR24 is linked to fatty liver disease.